Back to Search Start Over

NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of diet-induced obesity.

Authors :
Pellegrini C
Fornai M
Benvenuti L
Colucci R
Caputi V
Palazon-Riquelme P
Giron MC
Nericcio A
Garelli F
D'Antongiovanni V
Segnani C
Ippolito C
Nannipieri M
Lopez-Castejon G
Pelegrin P
Haskó G
Bernardini N
Blandizzi C
Antonioli L
Source :
British journal of pharmacology [Br J Pharmacol] 2021 Oct; Vol. 178 (19), pp. 3924-3942. Date of Electronic Publication: 2021 Jun 24.
Publication Year :
2021

Abstract

Background and Purpose: Enteric neurogenic/inflammation contributes to bowel dysmotility in obesity. We examined the role of NLRP3 in colonic neuromuscular dysfunctions in mice with high-fat diet (HFD)-induced obesity.<br />Experimental Approach: Wild-type C57BL/6J and NLRP3-KO (Nlrp3 <superscript>-/-</superscript> ) mice were fed with HFD or standard diet for 8 weeks. The activation of inflammasome pathways in colonic tissues from obese mice was assessed. The role of NLRP3 in in vivo colonic transit and in vitro tachykininergic contractions and substance P distribution was evaluated. The effect of substance P on NLRP3 signalling was tested in cultured cells.<br />Key Results: HFD mice displayed increased body and epididymal fat weight, cholesterol levels, plasma resistin levels and plasma and colonic IL-1β levels, colonic inflammasome adaptor protein apoptosis-associated speck-like protein containing caspase-recruitment domain (ASC) and caspase-1 mRNA expression and ASC immunopositivity in macrophages. Colonic tachykininergic contractions were enhanced in HFD mice. HFD NLRP3 <superscript>-/-</superscript> mice developed lower increase in body and epididymal fat weight, cholesterol levels, systemic and bowel inflammation. In HFD Nlrp3 <superscript>-/-</superscript> mice, the functional alterations of tachykinergic pathways and faecal output were normalized. In THP-1 cells, substance P promoted IL-1β release. This effect was inhibited upon incubation with caspase-1 inhibitor or NK <subscript>1</subscript> antagonist and not observed in ASC <superscript>-/-</superscript> cells.<br />Conclusion and Implications: In obesity, NLRP3 regulates an interplay between the shaping of enteric immune/inflammatory responses and the activation of substance P/NK <subscript>1</subscript> pathways underlying the onset of colonic dysmotility. Identifying NLRP3 as a therapeutic target for the treatment of bowel symptoms related to obesity.<br /> (© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)

Details

Language :
English
ISSN :
1476-5381
Volume :
178
Issue :
19
Database :
MEDLINE
Journal :
British journal of pharmacology
Publication Type :
Academic Journal
Accession number :
34000757
Full Text :
https://doi.org/10.1111/bph.15532